Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vomiting 2Nausea 2Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Brenner Tumor 1Breast Neoplasms 1

Interventions

Carboplatin 44Paclitaxel 43liposomal doxorubicin 23Topotecan 19Gemcitabine 18pembrolizumab 17Cyclophosphamide 17Bevacizumab 16Cisplatin 12niraparib 9olaparib 8fludarabine 7Taxes 7Docetaxel 7aldesleukin 6Nivolumab 6Doxorubicin 61-dodecylpyridoxal 6oregovomab 5fludarabine phosphate 5Peripheral Blood Stem Cell Transplantation 5Filgrastim 5rucaparib 4durvalumab 4avelumab 4Surgical Procedures, Operative 4Melphalan 4Ipilimumab 4Interleukin-2 4Etoposide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Ovarian Neoplasms × Granisetron × Clear all
NCT01275664 2018-05-22

Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer

GOG Foundation

Phase NA Terminated
4 enrolled 5 charts
Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms, Nausea, Ovarian Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡